Berlin, Germany

Rolf Bohlmann

USPTO Granted Patents = 64 

 

 

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 155(Granted Patents)

Forward Citations (Not Self Cited) = 134(Oct 12, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 1990-2022

Loading Chart...
Loading Chart...
Loading Chart...
64 patents (USPTO):

Title: Rolf Bohlmann: A Trailblazer in Pharmaceutical Innovations

Introduction

Rolf Bohlmann is a notable inventor based in Berlin, Germany, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 64 patents, he has made remarkable advancements in the treatment of various diseases through innovative compounds and compositions.

Latest Patents

Among his recent inventions are two groundbreaking patents. The first outlines the use of substituted dihydroimidazopyridinediones as inhibitors of MKNK1 and MKNK2. This invention details compounds with a general formula that can be utilized for preparing pharmaceutical compositions aimed at addressing hyperproliferative disorders, angiogenesis, inflammatory diseases, and conditions associated with inflammatory pain. The second patent focuses on 4-aryl-N-phenyl-1,3,5-triazin-2-amines incorporating a sulfoximine group. These compounds have similar applications, targeting hyper-proliferative disorders and various viral infections, offering new avenues for treatment and prevention.

Career Highlights

Rolf Bohlmann has a rich history in the pharmaceutical industry, having worked with renowned companies such as Schering Aktiengesellschaft and Bayer Intellectual Property GmbH. Through his innovative work, he has contributed significantly to the development of new therapeutic agents that address critical health issues.

Collaborations

Throughout his career, Bohlmann has collaborated with esteemed colleagues like Yukishige Nishino and Philip Lienau. These partnerships have facilitated the exchange of ideas and expertise, ultimately leading to the advancement of multiple patent applications and the development of effective medical solutions.

Conclusion

Rolf Bohlmann continues to be a driving force in the realm of pharmaceutical innovation. His extensive portfolio of patents reflects his dedication to advancing medical science and improving patient outcomes. As he builds on his career, the impact of his inventions will undoubtedly resonate within the healthcare industry for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…